Synthesis and biological evaluation of new asymmetrical bisintercalators as potential antitumor drugs

Journal of Medicinal Chemistry

Volumn 49, Issue 24, 2006, Pages 7198-7207

  Antonini, Ippolito ^a   Santoni, Giorgio ^a   Lucciarini, Roberta ^a   Amantini, Consuelo ^a   Sparapani, Silvia ^a   Magnano, Amelia ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIS(ACRIDINE 4 CARBOXAMIDE); BIS(IMIDAZOACRIDINE); BISNAFIDE MESYLATE; INTERCALATING AGENT; ISOQUINOLINE DERIVATIVE; LU 79553; MCI 3335; WMC 26; WMC 79;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DEGRADATION; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG SYNTHESIS; FLUOROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE ADENOCARCINOMA;

ACRIDINES; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL LINE, TUMOR; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INTERCALATING AGENTS; MALE; PROSTATIC NEOPLASMS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845357593     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0606793     Document Type: Article

References (32)

1. (a) Bousquet, P. F.; Braña, M. F.; Conlon, D.; Fitzgerald, K. M.; Perron, D.; Cocchiaro, C.; Miller, R.; Moran, M.; George, J.; Qian, X. D. Preclinical Evaluation of LU 79553: A Novel Bis-Naphthalimide with Potent Antitumor Activity. Cancer Res. 1995, 55, 1176-1180.
2. (b) Villalona-Calero, M. A.; Eder, J. P.; Toppmeyer, D. L.; Allen, L. F.; Fram, R.; Velagapudi, R.; Myers, M.; Amato, A.; Kagen-Hallet, K.; Razvillas, B.; Kufe, D. W.; Von Hoff, D. D.; Rowinsky, E. K. Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients with Solid Malignancies. J. Clin. Oncol. 2001, 19, 857-869.
3. (c) Gallego, J.; Reid, B. R. Solution Structure and Dynamics of a Complex between DNA and the Antitumor Bisnaphthalimide LU-79553: Intercalated Ring Flipping on the Millisecond Time Scale. Biochemistry 1999, 38, 15104-15115.
4. (d) Braña, M. F.; Ramos, A. Naphthalimides as Anti-Cancer Agents: Synthesis and Biological Activity. Curr. Med. Chem.: Anti-Cancer Agents 2001, 1, 237-255.
5. (a) O'Reilly, S.; Baker, S. D.; Sartorius, S.; Rowinsky, E. K.; Finizio, M.; Lubiniecki, G. M.; Grochow, L. B.; Gray, J. E.; Pieniaszek, H. J.; Donehower, R. C. A Phase I and Pharmacologic Study of DMP 840 Administered by 24-Hour Infusion. Ann. Oncol. 1998, 9, 101-104.
6. (b) Pavlov, V.; Kong Thoo Lin, P.; Rodilla, V. Cytotoxicity, DNA Binding and Localisation of Novel Bis-Naphthalimidopropyl Polyamine Derivatives. Chem.-Biol. Interact. 2001, 137, 15-24.
7. (c) Nitiss, J. L.; Zhou, J.; Rose, A.; Hsiung, Y.; Gale, K. C.; Osheroff, N. The Bis(naphthalimide) DMP-840 Causes Cytotoxicity by Its Action against Eukaryotic Topoisomerase II. Biochemistry 1998, 37, 3078-3085.
8. Braña, M. F.; Cacho, M.; Garcia, M. A.; de Pascual-Teresa, B.; Ramos, A.; Dominguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Banez-Coronel, M.; Lacal, J. C. New Analogues of Amonafide and Elinafide, Containing Aromatic Heterocycles: Synthesis, Antitumor Activity, Molecular Modeling, and DNA Binding Properties. J. Med. Chem. 2004, 47, 1391-1399.
9. Bailly, C.; Carrasco, C.; Joubert, A.; Bal, C.; Wattez, N.; Hildebrand, M.-P.; Lansiaux, A.; Colson, P.; Houssier, C.; Cacho, M.; Ramos, A.; Brãna, M. F. Chromophore-Modified Bisnaphthalimides: DNA Recognition, Topoisomerase Inhibition, and Cytotoxic Properties of Two Mono- and Bisfuronaphthalimides. Biochemistry 2003, 42, 4136-4150.
10. (a) Cholody, W. M.; Hernandez, L.; Hassner, L.; Scudiero, D. A.; Djurickovic, D. B.; Michejda, C. J. Bisimidazoacridones and Related Compounds: New Antineoplastic Agents with High Selectivity against Colon Tumors. J. Med. Chem. 1995, 38, 3043-3052.
11. (b) Tarasov, S. G.; Casas-Finet, J. R.; Cholody, W. M.; Kosakowska-Cholody, T.; Gryczynski, Z. K.; Michejda, C. J. Bisimidazoacridones: 2. Steady-state and Time-Resolved Fluorescence Studies of their Diverse Interactions with DNA. Photochem. Photobiol. 2003, 78, 313-322.
12. Antonini, I.; Polucci, P.; Magnano, A.; Gatto, B.; Palumbo, M.; Menta, E.; Pescalli, N.; Martelli, S. Design, Synthesis, and Biological Properties of New Bis(acridine-4-carboxamides) as Anticancer Agents. J. Med. Chem. 2003, 46, 3109-3115.
13. Antonini, I.; Polucci, P.; Magnano, A.; Sparapani, S.; Martelli, S. Rational Design, Synthesis and Biological Evaluation of Bis-(pyrimido[5,6,1-de] acridines) and Bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as New Anticancer Agents. J. Med. Chem. 2004, 47, 5244-5250.
14. (a) Cholody, W. M.; Kosakowska-Cholody, T.; Hollingshead, M. G.; Hariprakasha, H. K.; Michejda, C. J. A New Synthetic Agent with Potent but Selective Cytotoxic Activity against Cancer. J. Med. Chem. 2005, 48, 4474-4481.
15. (b) Kosakowska-Cholody, T.; Cholody, W. M.; Monks, A.; Woynarowska, B. A.; Michejda, C. J. WMC-79, a Potent Agent against Colon Cancers, Induces Apoptosis Through a P53-Dependent Pathway. Mol. Cancer Ther. 2005, 4, 1617-1627.
16. Cherney, R. J.; Swartz, S. G.; Patten, A. D.; Akamike, E.; Sun, J. H.; Kaltenbach, R. F.; Seitz, S. P.; Behrens, C. H.; Getahun, Z.; Trainor, G. L.; Vavala, M.; Kirshenbaum, M. R.; Papp, L. M.; Stafford, M. P.; Czerniak, P. M.; Diamond, R. J.; McRipley, R. J.; Page, R. J.; Gross, J. L. The Synthesis and Antitumor Evaluation of Unsymmetrical Bis-Imides. Bioorg. Med. Chem. Lett. 1997, 7, 163-168.
17. Spicer, J. A.; Gamage, S. A.; Finlay, G. J.; Denny, W. A. Synthesis and Evaluation of Unsymmetrical Bis(Arylcarboxamides) Designed as Topoisomerase-Targeted Anticancer Drugs. Bioorg. Med. Chem. 2002, 10, 19-29.
18. Antonini, I.; Polucci, P.; Jenkins, T. C.; Kelland, L. R.; Menta, E.; Pescalli, N.; Stefanska, B.; Mazerski, J.; Martelli, S. 1-[(ω-Aminoalkyl) amino]-4-[N-(ω-aminoalkyl)carbamoyl]-9-oxo-9,10-dihydroacridines as Intercalating Cytotoxic Agents: Synthesis, DNA Binding, and Biological Evaluation. J. Med. Chem. 1997, 40, 3749-3755.
19. Antonini, I.; Cola, D.; Polucci, P.; Bontemps-Gracz, M.; Borowski, E.; Martelli, S. Synthesis of (Dialkylamino)alkyl-Disubstituted Pyrimido[5,6,1-de] acridines, a Novel Group of Anticancer Agents Active on a Multidrug Resistant Cell Line. J. Med. Chem. 1995, 38, 3282-3286.
20. Antonini, I.; Polucci, P.; Kelland, L. R.; Menta, E.; Pescalli, N.; Martelli, S. 2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione Derivatives: A Class of Cytotoxic Agents Active on Multidrug Resistant Cell Lines. Synthesis, Biological Evaluation and Structure-Activity Relationships. J. Med. Chem. 1999, 42, 2535-2541.
21. Antonini, I.; Polucci, P.; Magnano, A.; Gatto, B.; Palumbo, M.; Menta, E.; Pescalli, N.; Martelli, S. 2,6-Di(ω-aminoalkyl)-2,5,6,7- tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: Novel, Potent, Cytotoxic, and DNA-Binding Agents. J. Med. Chem. 2002, 45, 696-702.
22. Cholody, W. M.; Martelli, S.; Konopa, J. 8-Substituted 5-[(Aminoalkyl)amino]-6H-ν-triazolo[4,5,1-de]acridin-6-ones as Potential Antineoplastic Agents. Synthesis and Biological Activity. J. Med. Chem. 1990, 33, 2852-2856.
23. (a) McConnaughie, A. W.; Jenkins, T. C. Novel Acridine-Triazenes as Prototype Combilexins: Synthesis, DNA Binding and Biological Activity. J. Med. Chem. 1995, 38, 3488-3501.
24. (b) Jenkins, T. C. Optical Absorbance and Fluorescence Techniques for Measuring DNA-Drug Interactions. In Methods in Molecular Biology, Vol. 90: Drug-DNA Interaction Protocols; Fox, K. R., Ed.; Humana Press: Totawa, NJ, 1997; Chapter 14, pp 195-218.
25. (a) Morgan, A. R.; Lee, J. S.; Pulleyblank, D. E.; Murray, N. L.; Evans, D. H. Review: Ethidium Fluorescence Assays. Part 1. Physicochemical Studies. Nucleic Acids Res. 1979, 7, 547-569.
26. (b) Baguley, B. C.; Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential Antitumor Agents. 34. Quantitative Relationships between DNA Binding and Molecular Structure for 9-Anilinoacridines Substituted in the Anilino Ring. J. Med. Chem. 1981, 24, 170-177.
27. Bailly, C.; Pommery, N.; Houssin, R.; Hénichart, J.-P. Design, Synthesis. DNA Binding, and Biological Activity of a Series of DNA Minor Groove-Binding Intercalating Drugs. J. Pharm. Sci. 1989, 78, 910-917.
28. Feigon, J.; Denny, W. A.; Leupin, W.; Kearns, D. R. Interactions of Antitumor Drugs with Natural DNA: Proton NMR Study of Binding Mode and Kinetics. J. Med. Chem. 1984, 27, 450-65.
29. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National-Cancer- Institute - Cancer Drug Discovery and Development Program. Semin. Oncol. 1992, 19, 622-638.
30. Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A Novel Assay for Apoptosis - Flow Cytometric Detection of Phosphatidylserine Expression on Early Apoptotic Cells Using Fluorescein-Labeled Annexin-V. J. Immunol. Methods 1995, 184, 39-51.
31. Sandstrom, K.; Hakansson, L.; Lukinius, A.; Venge, P. A Method to Study Apoptosis in Eosinophils By Flow Cytometry. J. Immunol. Methods 2000, 240, 55-68.
32. Matassov, D.; Kagan, T.; Leblanc, J.; Sikorska, M.; Zakeri, Z. Measurement of Apoptosis by DNA Fragmentation. Methods Mol. Biol. 2004, 282, 1-17.